Pharma

Qiagen Weighs Stake Sale In $1 Billion Bioinformatics Arm- Bloomberg News

  • January 27, 2023 04:22 PM CET | Reuters
 Qiagen Weighs Stake Sale In $1 Billion Bioinformatics Arm- Bloomberg News

Jan 27 (Reuters) - * QIAGEN WEIGHS STAKE SALE IN $1 BILLION BIOINFORMATICS ARM- BLOOMBERG NEWS Source text: https://bloom.bg/3JmEh2M

Read More...

Pharvaris Announces Positive Top-Line Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks

Pharvaris Announces Positive Top-Line Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks

  • December 08, 2022 02:14 PM CET | Reuters

Dec 8 (Reuters) - Pharvaris NV: * PHARVARIS ANNOUNCES POSITIVE TOP-LINE PHASE 2 DATA FROM RAPIDE-1 STUDY OF PHVS416 FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS * PHARVARIS NV - PRIMARY ENDPOINT MET,

Read More...
Pharvaris Reports Third Quarter 2022 Financial Results And Provides Business Update

Pharvaris Reports Third Quarter 2022 Financial Results And Provides Business Update

  • December 08, 2022 02:13 PM CET | Reuters

Dec 8 (Reuters) - Pharvaris NV: * PHARVARIS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE * PHARVARIS NV - EXECUTING FROM A STRONG FINANCIAL POSITION WITH CASH AND CASH

Read More...
Pharvaris NV <PHVS.O>: Losses of 25  cents announced for third quarter

Pharvaris NV <PHVS.O>: Losses of 25  cents announced for third quarter

  • December 08, 2022 01:35 PM CET | Reuters

8 December 2022 12:35 p.m. ​All figures in euros. The loss announced by Pharvaris NV in the third quarter were higher than the Refinitiv mean estimate of losses. The company reported losses of -25

Read More...
Pharvaris NV reports results for the quarter ended in September - Earnings Summary

Pharvaris NV reports results for the quarter ended in September - Earnings Summary

  • December 08, 2022 01:35 PM CET | Reuters

* Pharvaris NV reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended in September. The mean expectation of five analysts for the quarter was for a loss of 63 cents per share

Read More...
Pharvaris NV <PHVS.O>: A loss of 63 cents per share anticipated for third quarter

Pharvaris NV <PHVS.O>: A loss of 63 cents per share anticipated for third quarter

  • November 23, 2022 12:02 PM CET | Reuters

23 November 2022 11:02 a.m. All figures in euros. Pharvaris NV is expected to show a decrease in its third quarter earnings to -63 cents​ per share according to the mean Refinitiv estimate from five

Read More...
Pharvaris NV expected to post a loss of 63 cents a share - Earnings Preview

Pharvaris NV expected to post a loss of 63 cents a share - Earnings Preview

  • November 23, 2022 12:01 PM CET | Reuters

* Pharvaris NV is expected to show no change in quarterly revenue when it reports results on November 25 (estimated). * * ​Refinitiv's mean analyst estimate for Pharvaris NV is for a loss of 63 cents

Read More...
LAVA Therapeutics NV <LVTX.O>: A loss of 14 cents per share anticipated for third quarter

LAVA Therapeutics NV <LVTX.O>: A loss of 14 cents per share anticipated for third quarter

  • November 11, 2022 06:04 PM CET | Reuters

11 November 2022 05:04 p.m. All figures in euros. LAVA Therapeutics NV is expected to show an increase in its third quarter earnings to -14 cents​ per share according to the mean Refinitiv estimate

Read More...
ProQR Therapeutics NV reports results for the quarter ended in September - Earnings Summary

ProQR Therapeutics NV reports results for the quarter ended in September - Earnings Summary

  • November 09, 2022 02:50 PM CET | Reuters

* ProQR Therapeutics NV reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended in September. The mean expectation of seven analysts for the quarter was for a loss of 21 cents

Read More...
ProQR Therapeutics NV <PRQR.O>: Losses of 34  cents announced for third quarter

ProQR Therapeutics NV <PRQR.O>: Losses of 34  cents announced for third quarter

  • November 09, 2022 02:50 PM CET | Reuters

9 November 2022 01:50 p.m. ​All figures in euros. The loss announced by ProQR Therapeutics NV in the third quarter were lower than the Refinitiv mean estimate of losses. The company reported losses of

Read More...
Proqr Announces Q3 2022 Operating And Financial Results

Proqr Announces Q3 2022 Operating And Financial Results

  • November 09, 2022 01:38 PM CET | Reuters

Nov 9 (Reuters) - Proqr Therapeutics Nv: * PROQR ANNOUNCES THIRD QUARTER 2022 OPERATING AND FINANCIAL RESULTS * QTRLY LOSS PER SHARE EUR 0.34 * REPAYMENT OF DEBT WITH CASH RUNWAY INTO 2026 * Q3

Read More...

Frequently Asked Questions

3232